Color Vision Tied to Bladder Survival
Patients with impaired color perception may be less likely to recognize blood in urine, potentially delaying diagnosis of cancers that rely on visible bleeding as an early warning sign.
A retrospective cohort study reveals that patients with bladder cancer and color vision deficiency (CVD) have a significantly poorer overall survival rate and a 52% higher 20-year mortality risk compared to those without CVD. In contrast, colorectal cancer patients showed no survival differences based on color vision status. CVD, which affects the ability to distinguish red hues, may lead to delays in recognizing visible blood, a common symptom in bladder cancer. This raises concerns about recognition and diagnosis of bladder cancer in individuals with CVD, with potential implications for clinical monitoring. Researchers propose further studies to assess the impact of CVD on cancer diagnoses and outcomes.
1. Patients with bladder cancer and CVD face 52% higher mortality risk. 2. CVD may delay recognition of blood in urine. 3. Colorectal cancer outcomes are not affected by CVD. 4. Screening for colorectal cancer starts at age 45. 5. Study relies on retrospective health records; diagnostic coding limitations exist. 6. No changes to clinical practice recommended yet. 7. Future research needed on CVD screening in cancer patients. 8. Awareness of CVD's implications on bladder cancer diagnosis is crucial.